Cargando…

Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats

The tyrosine kinase (TK) inhibitor imatinib provides a highly effective therapy for chronic myeloid leukemia (CML) via inhibition of the oncogenic TK BCR-ABL1. However, off-target TKs like platelet-derived growth factor receptors (PDGF-R) and colony-stimulating factor-1 receptor (c-fms), involved in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tauer, Josephine T., Hofbauer, Lorenz C., Jung, Roland, Gerdes, Sebastian, Glauche, Ingmar, Erben, Reinhold G., Suttorp, Meinolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479438/ https://www.ncbi.nlm.nih.gov/pubmed/26107505 http://dx.doi.org/10.1371/journal.pone.0131192

Ejemplares similares

Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth
por: Tauer, Josephine Tabea, et al.
Publicado: (2013)

Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment
por: Jaeger, Bernadette Anna Sophia, et al.
Publicado: (2012)

Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia
por: Volz, Christian, et al.
Publicado: (2023)

Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment
por: Bettoni da Cunha-Riehm, Claudia, et al.
Publicado: (2020)

Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data
por: Fassoni, Artur C., et al.
Publicado: (2018)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

Mathematical Modeling of Oncogenesis Control in Mature T-Cell Populations
por: Gerdes, Sebastian, et al.
Publicado: (2013)

Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia
por: Kesely, Kristina R., et al.
Publicado: (2016)

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
por: Tanaka, Atsushi, et al.
Publicado: (2019)

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
por: Glauche, Ingmar, et al.
Publicado: (2018)

Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib
por: Kim, T-M, et al.
Publicado: (2011)

The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice
por: Stephens, R Scott, et al.
Publicado: (2015)

Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat
por: Wang-Rosenke, Yingrui, et al.
Publicado: (2013)

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
por: Ananthula, Hari Krishna, et al.
Publicado: (2018)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton
Publicado: (1989)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
por: Millot, Frédéric, et al.
Publicado: (2021)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
por: Mahadevan, Daruka, et al.
Publicado: (2014)

Caenorhabditis Intervention Testing Program: the tyrosine kinase inhibitor imatinib mesylate does not extend lifespan in nematodes
por: Coleman-Hulbert, Anna L., et al.
Publicado: (2019)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib
por: Beckmann, Svenja, et al.
Publicado: (2014)

The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice
por: Reber, Laurent L., et al.
Publicado: (2017)

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
por: Nteliopoulos, Georgios, et al.
Publicado: (2019)

Splenomegaly in Children and Adolescents
por: Suttorp, Meinolf, et al.
Publicado: (2021)

Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery
por: Kim, In Kyoung, et al.
Publicado: (2013)

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
por: Hirao, Takuya, et al.
Publicado: (2017)

In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models
por: Baek, Yi-Yong, et al.
Publicado: (2021)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology
por: Hoffmann, Katja, et al.
Publicado: (2020)

Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia
por: Suttorp, Meinolf, et al.
Publicado: (2020)

Effects of Spaceflight on Bone Microarchitecture in the Axial and Appendicular Skeleton in Growing Ovariectomized Rats
por: Keune, Jessica A., et al.
Publicado: (2015)

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells
por: Shi, Ping, et al.
Publicado: (2010)

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models
por: Crawford, L J, et al.
Publicado: (2014)

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2015)

Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice
por: Gergely, Péter Attila, et al.
Publicado: (2019)

Mechanistic models of blood cell fate decisions in the era of single-cell data
por: Glauche, Ingmar, et al.
Publicado: (2021)

Chronic Myeloid Leukemia in Children: Immune Function and Vaccinations
por: Suttorp, Meinolf, et al.
Publicado: (2021)

Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors
por: Huang, Xuan, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_t9s2tr5h6qs4g5g386kfh2qn3g